Objectives: Interpretation of drug resistance mutation (DRM) has been based solely on HIV-1 subtype B. Reverse transcriptase (RT) C-terminal domains have been disregarded in resistance interpretation, as their clinical relevance is still controversial. We determined the emergence of DRM in RT C-terminal domains of different HIV-1 subtypes, the genetic barrier for the acquisition of these DRM and their temporal appearance with 'classical' RT inhibitor (RTI) mutations.
Introduction
Human immunodeficiency virus type 1 (HIV-1) genetic diversity has allowed virus classification into types, groups, subtypes, subsubtypes and recombinant forms. 1 The design of antiretroviral drugs, the mapping of drug resistance mutations (DRMs) and the development of genotype interpretation algorithms have been based on HIV-1 subtype B. 2 However, this subtype represented only 10% of novel infections in 2007 and is prevalent only in developed countries. 3 Recent interest in anti-HIV therapy efficacy and drug resistance development in patients infected with non-B subtypes is therefore paramount. Genetic differences between HIV-1 strains modify viral protein structures and therefore can impair drug binding and efficacy. 2 Reverse transcriptase (RT) inhibitors (RTIs) of the non-nucleoside class, for example, are ineffective against HIV-2 and HIV-1 group O. 4, 5 HIV RT is a heterodimer with two catalytic activities: polymerization of double-stranded DNA, conferred by its polymerase (POL) domain (codons 1-300), and cleavage of viral template RNA, catalysed by its RNase H (RNH) domain (codons 441-560). POL has been the target of two major classes of antiretroviral drugs, 6 and therefore various DRMs have emerged in this domain. 6 RT C-terminal domains were disregarded in genotyping assays until 2005, when mutations in RNH were shown to impair template RNA degradation during reverse transcription, conferring additional time for RTI excision. 7 The importance of the connection domain (CN, codons 301 -440) in resistance was evident with the demonstration that N348I and T369I/V confer resistance to 8, 9 Other DRM in CN and RNH do not directly decrease drug susceptibility, but increase resistance conferred by thymidine analogue mutations. 9 -12 The limited number of entire viral RT sequences from treated patients has prevented an assessment of the clinical relevance of DRM in RT C-terminal domains. Some studies showed reduced susceptibility to RTIs and/or treatment failure associated with definite CN DRM. 13, 14 One study suggested no correlation between therapeutic failure and CN DRM, 15 while another showed a minor effect of those mutations in etravirine failure. 16 Whether CN and RNH DRMs emerge early in treatment failure or only in multiply failed patients remains unknown.
Some RT CN DRMs appear to be polymorphic in non-B subtypes, further preventing elucidation of their role in resistance.
HIV-1 RT C-terminal sequences were obtained from information from 6087 treatment-naive and 3795 RTI-treated patients deposited in the Stanford HIV Drug Resistance Database 18 (accessed June 2013). Sequences of five HIV-1 subtypes and two major recombinant forms (A, n ¼ 394 naive and 82 treated; B, n ¼ 3055 and 3118; C, n ¼ 1302 and 195; F, n ¼ 154 and 48; G, n ¼ 232; CRF01_AE, n ¼ 281 and 182; and CRF02_AG, n ¼ 669 and 170) were retrieved. All sequences contained entire or partial CN and/or RNH regions and included the POL domain.
The DRMs previously characterized in HIV-1 CN and RNH domains G335D, N348I, A360V, T369I/V, A371V, A376S, A400T, D488E, Q509L and Q547K 8 -12,19,20 were analysed. Differences in the proportions of mutations for each subtype relative to HIV-1 subtype B were evaluated by x 2 tests with Yate's correction, and P,0.05 was considered significant. Amino acid substitutions were considered polymorphisms when their frequency varied between 1% and 95% and genetic signatures had a frequency .95%.
HIV-1 sequences derived from patients under RTI-based treatment of two groups, 862 without non-nucleoside RTI (NNRTI)-based regimens (1 -7 NRTI and 0 NNRTI; group 1) and 2933 with both NRTI and NNRTI exposure (1-7 NRTI and 1 -4 NNRTI; group 2), had their CN and RNH amino acid sequences deduced from nucleotide sequences. Major DRMs N348I and T369I/V and the other compensatory/secondary DRMs were compiled. Comparison of DRM proportions in treatment-naive versus RTI-treated groups per subtype was performed with x 2 tests with Yate's correction. The emergence of RT C-terminal DRM with respect to RT POL DRM was exclusively analysed in subtype B due to the availability of a large number of sequences exposed to RTIs: 682 in group 1 and 2436 in group 2. Sequences of both groups were categorized according to the number of major DRM in the POL domain as defined in Johnson et al., 6 and the number of RT C-terminal mutations. The x 2 tests for trend were performed to correlate the emergence of mutations in both domains.
To verify whether individual HIV-1 subtypes harbour genetic signatures that could modulate the acquisition of specific DRM in RT C-terminal domains, sequences from treatment-naive patients were grouped by subtype and the composition of each codon associated with DRM was determined as previously described. 21 The HXB2 sequence (subtype B; GenBank no. K03455) was used as wild-type. Comparison of polymorphism frequencies for each subtype with respect to HXB2 was performed by x 2 tests with Yate's correction.
Results
The RT CN polymorphisms G335D and A371V were abundant (.80%) in treatment-naive sequences of several non-B subtypes ( Table 1 ). The major NNRTI-related mutations N348I and T369I had a low frequency in treatment-naive sequences (,1% and ,0.4%, respectively). However, T369V was present in 11% of treatment-naive subtype A and CRF02_AG sequences. A360V was also observed at low prevalence (,1%) in treatment-naive sequences of seven HIV-1 genetic forms, while the A371V mutation was abundant in most subtypes, except for B and C (3%). The RNH mutations D488E, I509L and Q547K were rare (0%-2%) in all HIV-1 forms.
All HIV-1 variants selected at least three different mutations in CN upon treatment exposure ( Table 1 ). Selection of N348I was observed in all subtypes. In contrast, T369I was not selected under RTI treatment in any HIV-1 genetic form analysed, except for subtype C viruses of treatment group 2. A360V and T369V were selected by RTI treatment in subtypes A, B and CRF01_AE. A371V was selected in subtypes B and C, while in subtype A and related recombinant forms it appeared as a signature. G335D was not selected by RTIs in any HIV-1 subtype, but it slightly increased in subtype C upon treatment. A376S appeared correlated with treatment in subtypes A, B, C and CRF02_AG, while A400T was selected in subtype B and CRF02_AG. There was no evidence of DRM selection in the RNH domain.
We next analysed the emergence of CN mutations in subtype B viruses according to the number of POL domain mutations, and we observed that most of them increased in frequency (Figure 1a) . CN mutations did not emerge alone, but their presence appeared early, correlated with drug resistance in POL. The proportion of N348I, T369V and A376S was higher with the combined use of both RTI classes (group 2), while A360V, A371V and A400T arose more frequently with exclusive exposure to NRTI (group 1).
The calculated genetic barrier showed that the acquisition of N348I, A371V, D488E, Q509L and Q547K is similar across all HIV-1 genetic forms (Figure 1b) . For the acquisition of G335D, 68% of subtype F isolates needed two changes (score of 3.5) in contrast to the remaining subtypes, which needed only one change (score of 1.0). Isolates carrying T369 needed only one transition (ts) to acquire 369I, as well as those carrying A369 to acquire 369V. Emergence of 376S appeared less likely in subtype A isolates harbouring V376 (score of 3.5). Other subtypes presented A376 or T376 (78%-94%), needing only one ts to acquire 376S. Finally, 21% of subtype C isolates presented I400, which showed a higher barrier to acquiring 400T (two ts) than A400 (one ts).
Discussion
In the present work we showed for the first time that HIV-1 RT CN DRM can be selected in a wide range of HIV-1 genetic forms. Mutations in this domain have been previously reported, but have been restricted to individual HIV-1 subtypes.
HIV-1 non-B subtypes carry genomic polymorphisms that correspond to compensatory DRMs in subtype B. Herein, A371V was pointed out as a genetic signature of CRF01_AE and was present in a large proportion of subtype A and CRF02_AG isolates, as previously shown. 22, 23 However, it was rare in treatment-naive d Underlined values correspond to frequency of DRM that differs significantly (P, 0.05) between drug-naive sequences of each non-B subtype compared with subtype B. e Numbers in parentheses correspond to percentages of total sequences of each subtype carrying each specific mutation. f Bold type indicates statistical significance between treatment naive versus treated for a given subtype (P,0.05).
subtype B and C isolates. G335D and A400T also appeared to be polymorphisms, while six other DRM were rare in all HIV-1 forms studied: N348I, A360V, T369I, D488E, I509L and Q547K. The estimated genetic barrier could partly explain differences in DRM emergence among distinct HIV-1 subtypes, but some disparities were observed. For example, 369V should be more easily selected in subtype A compared with other subtypes. Indeed, one-third of subtype A isolates exposed to both RTI classes presented 369V. In agreement with that, subtype B accumulated 369I, but subtype C and CRF01_AE selected for 369V, different from the expected outcome. A possible explanation for this phenomenon is the impact of 369V on the replicative capacity of distinct subtypes. 24 Further studies are necessary to confirm this hypothesis.
Fitness cost could explain why N348I (score of 2.5) was more selected than T369I/V (score of 1 or 2) in subtype B independent of the RTI class used. Seven CN and RNH codons need only one ts to acquire the respective DRM, including G335D, A360V, T369I, CAR  D488E  GAY  I400T  ACH  A400T  GCN  V376S  GTN  T376S  ACN  A376S  GCN  A371V  GCN   GCG  A369I   GCH   T360V  ACN  A360V  GCN  N348I  AAY   GCG  A369V   GCH   ACG  T369I   ACH   ACG  T369V   ACH   GGR  G335D GGY 0% 20% 40% 60%80%100% 0% 20% 40% 60% 80% 100% 0% 20% 40% 60% 80% Score 1 2 2.5 3 3.5 100% 0% 20% 40% 60% 80% 100% 0% 20% 40% 60% 80% 100% 0% 20% 40% 60% 80% 100% 0% 20% 40% 60% 80% 100% A369V and A371V. However, our analysis of treatment-experienced patients revealed that G335D was not selected in subtype B, while 369I/V were rare in most subtypes; 400T was selected in subtype B under NRTI treatment and in CRF02_AG under NRTI/NNRTI treatment. Interestingly, the proportion of this mutation decreased in subtype B under NRTI/NNRTI treatment, a fact that requires further assessment. We also observed that three RNH DRM previously reported in vivo-D488E, Q509L and Q547K 9,11 -were absent in our sequences.
N348I was shown to arise early in drug therapy failure, 8 while A360V and A371V correlated with the number of thymidine analogue mutations. 9 Here, we further extend the observation of early emergence to A360V, A371V, A376S and A400T in subtype B isolates under RTI exposure. Such early emergence can influence treatment efficacy and durability, and deserves attention.
In conclusion, we showed that some HIV-1 RT connection mutations are selected in all HIV-1 genetic forms, while others are present as genetic signatures of specific subtypes. The calculated genetic barrier highlighted, in general, a low barrier to resistance acquisition in the RT C-terminal domains and an early selection of these mutations during RTI failure.
